Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues
- 664 Downloads
Topoisomerase II α enzyme plays a critical role in DNA replication process. It controls the topologic states of DNA during transcription and is essential for cell proliferation. Human DNA topoisomerase II α (hTopo II α) is a promising chemotherapeutic target for anticancer agents against a variety of cancer types. In the present study, andrographolide and its structurally modified analogues were investigated for their inhibitory activities on hTopo II α enzyme. Five out of nine andrographolide analogues potently reduced hTopo II α activity and inhibited cell proliferation in four mammalian cell lines (Hela, CHO, BCA-1 and HepG2 cells). IC50 values for cytotoxicity of analogues 3A.1, 3A.2, 3A.3, 1B and 2C were 4 to 7 μM. Structure-activity relationship studies revealed that both core structure of andrographolide and silicon based molecule of functional group were important for the inhibition of hTopo II α activity whereas position C-19 of analogues was required for anti-proliferation. In addition, the analogue 2C at 10 μM concentration inhibited hTopo II α, and induced apoptosis with nuclear fragmentation and formation of apoptotic bodies in HepG2 cells. The analogue 2C may, therefore, have a therapeutic potential as effective anticancer agent targeting the hTopo II α functions.
KeywordsAndrographolide analogues Apoptosis Cancer DNA topoisomerase II α inhibitor
This research project is supported by Mahidol University, the Center of Excellence on Environmental Health, Toxicology, Science & Technology Postgraduate Education and Research Development Office (PERDO), Ministry of Education, Thailand, and the Office of the Higher Education Commission and Mahidol University under the National Research universities (NRU). We are grateful to Prof. Chumpol Pholpramool for his critical reading on the manuscript.
Conflict of interest
- 6.Jada SR, Matthews C, Saad MS, Hamzah AS, Lajis NH, Stevens MF, Stanslas J (2008) Benzylidene derivatives of andrographolide inhibit growth of breast and colon cancer cells in vitro by inducing G(1) arrest and apoptosis. Br J Pharmacol 155:641–654. doi: bjp.2008.368/bjp.2008.368 PubMedCrossRefGoogle Scholar
- 8.Nanduri S, Nyavanandi VK, Thunuguntla SS, Kasu S, Pallerla MK, Ram PS, Rajagopal S, Kumar RA, Ramanujam R, Babu JM, Vyas K, Devi AS, Reddy GO, Akella V (2004) Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents. Bioorg Med Chem Lett 14:4711–4717. doi: 10.1016/j.bmcl.2004.06.090 PubMedCrossRefGoogle Scholar
- 16.Pourquier P, Kohlhagen G, Ueng JM, Pommier Y (2009) Topoisomerase I and II activity assays, Form; Method in Molecular Medicine, Vol 28. In: Brown R, Böger-Brown U (eds) Cytotoxic drug resisance mechanisms. Humana Press INC, Totowa, pp 95–110Google Scholar
- 18.Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, Yalowich JC (1997) Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 53:1843–1853. doi: 10.1016/S0006-2952(97)00013-0 PubMedCrossRefGoogle Scholar
- 20.Sabisz M, Wesierska-Gadek J, Skladanowski A (2010) Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. Biochem Pharmacol 79:1387–1397. doi: 10.1016/j.bcp.2009.12.023 PubMedCrossRefGoogle Scholar
- 21.Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson Strode J, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL, Latus LJ, Pommier Y, Burke TG (2000) The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970–3980. doi: 10.1021/jm000144o PubMedCrossRefGoogle Scholar
- 25.Onda T, Toyoda E, Miyazaki O, Seno C, Kagaya S, Okamoto K, Nishikawa K (2008) NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors. Cancer Lett 259:99–110. doi: 10.1016/j.canlet.2007.10.004 PubMedCrossRefGoogle Scholar